IP Library › Granted Patent US 12,559,729
Granted Patent B2
US 12,559,729 · App. 15/815,610 · Granted Feb 24, 2026

Induction of hepatocytes by stem cell differentiation with RNA

Inventors: Jiwu Wang (La Jolla, CA); Yuhui Ni (San Diego, CA); Yuanyuan Zhao (San Diego, CA)
Assignee: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.
C12N5/0696A61K35/407A61K35/545C12N5/067C12N5/0672C12N2310/11C12N2501/60C12N2506/03C12N2506/45C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,729
App. No.
15/815,610
Granted
Feb 24, 2026
Kind
B2
Abstract

A novel method of inducing or producing hepatocytes from human induced pluripotent stem cells at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered mRNAs at multiple critical differentiation decision points along a pluripotent to mesendoderm to endoderm to hepatocytes pathway in a previously unknown manner.

Claims (42)

1 . A method of inducing differentiation of stem cells into hepatocytes, comprising the steps of:

(a) culturing induced pluripotent stem cells as starting cells;

(b) inducing differentiation of said starting cells into a mesendoderm lineage;

(c) generating endoderm cells by culture cell transfection of the said mesendoderm lineage cells with a first combination of mRNAs encoding endodermal differentiation factors, wherein the first combination of mRNAs comprises FoxA2 or Sox17 mRNAs;

(d) generating hepatic progenitor cells by culture cell transfection of said endoderm cells with a second combination of mRNAs encoding hepatic progenitor cell differentiation factors, wherein the second combination of mRNAs comprises one or more of Tbx3, GATA4, GATA6, and Hex mRNAs;

(e) generating hepatocytes by culture cell transfection of said hepatic progenitor cells with a third combination of mRNAs encoding hepatocyte maturation factors to form cell clusters, wherein the third combination of mRNAs comprises one or more of HNF4a, HNF1a, HNF6, CEB/Pa, and CEB/Pb mRNAs;

wherein the differentiation factors of steps (c) and (d), and the maturation factors present in the cell cultures of step (e) consist of transcription factors introduced by mRNA transfections; wherein steps (c) to (e) do not employ polypeptide growth factors in the culture medium that guide generation of hepatocytes; and

(f) obtaining said hepatocytes by collecting said clusters formed from said hepatic progenitor cells and replating said clusters to obtain monolayers of hepatocytes.

2 . The method of claim 1 , wherein said first combination of mRNAs comprises FoxA2 mRNAs.

3 . The method of claim 1 , wherein said first combination of mRNAs comprises Sox17 mRNAs.

4 . The method of claim 1 , wherein said first combination of mRNAs comprises FoxA2 and Sox17 mRNAs.

5 . The method of claim 1 , wherein said first combination of mRNAs comprises FoxA2, Sox17, GATA4, and GATA6 mRNAs.

6 . The method of claim 1 , wherein said second combination of mRNAs comprises Hex mRNAs.

7 . The method of claim 1 , wherein said second combination of mRNAs comprises Tbx3 mRNAs.

8 . The method of claim 1 , wherein said second combination of mRNAs comprises Tbx3 and Hex mRNAs.

9 . The method of claim 1 , wherein said second combination of mRNAs comprises Tbx3, GATA4, GATA6, and Hex mRNAs.

10 . The method of claim 1 , wherein said third combination of mRNAs comprises HNF1a mRNAs.

11 . The method of claim 1 , wherein said third combination of mRNAs comprises HNF4a mRNAs.

12 . The method of claim 1 , wherein said third combination of mRNAs comprises HNF4a, HNF1a, HNF6, CEB/Pa, and CEB/Pb mRNAs.

13 . The method of claim 1 , wherein said starting cells are harvested from a body fluid or tissue of a subject.

14 . A method of producing differentiated hepatocytes from induced pluripotent stem cells, comprising the steps of:

(a) culturing said induced pluripotent stem cells as starting cells;

(b) inducing differentiation of said starting cells into a mesendoderm lineage;

(c) generating endoderm cells by culture cell transfection of said mesendoderm lineage cells with a first combination of mRNAs encoding endodermal differentiation factors, wherein the first combination of mRNAs comprises FoxA2 or Sox17 mRNAs;

(d) generating hepatic progenitor cells by transfection of said endoderm cells with a second combination of mRNAs encoding hepatic progenitor cell differentiation factors, wherein the second combination of mRNAs comprises one or more of Tbx3, GATA4, GATA6, and Hex mRNAs;

(e) generating hepatocytes by transfection of said hepatic progenitor cells with a third combination of mRNAs encoding hepatocyte maturation factors to form cell clusters, wherein the third combination of mRNAs comprises one or more of HNF4a, HNF1a, HNF6, CEB/Pa, and CEB/Pb mRNAs;

wherein differentiation factors of steps (c) and (d), and maturation factors of step (e) consist of transcription factors introduced by mRNA transfections, wherein steps (c) to (e) do not employ polypeptide growth factors in the culture medium that guide generation of hepatocytes; and

(f) obtaining said hepatocytes by passaging said clusters into monolayers to obtain hepatocytes or collecting said clusters formed from said hepatic progenitor cells and replating said clusters to obtain monolayers of hepatocytes.

15 . A method for producing endoderm cells from induced pluripotent stem cells, comprising the steps of:

(a) culturing said induced pluripotent stem cells as starting cells;

(b) inducing differentiation of said starting cells into a mesendoderm lineage; and

(c) generating endoderm cells by culture cell transfection of said mesendoderm lineage with a combination of mRNAs encoding endodermal differentiation factors comprising FoxA2 and/or Sox17 mRNAs in an effective dose and within specific time windows, and wherein the differentiation factors consist of transcription factors introduced by mRNA transfections, and polypeptide growth factors in the culture medium that guide generation of endoderm cells are not employed.

16 . The method of claim 1 , wherein the hepatocytes are footprint-free.

17 . The method of claim 1 , wherein steps (c) to (e) do not employ type-specific growth factor proteins in the culture medium.

18 . The method of claim 14 , wherein the hepatocytes are footprint-free.

19 . The method of claim 14 , wherein steps (c) to (e) do not employ cell type-specific growth factor proteins in the culture medium.

20 . The method of claim 15 , wherein the endoderm cells are footprint-free.

21 . The method of claim 15 , wherein step (c) does not employ endoderm-specific growth factor proteins in the culture medium.

22 . The method of claim 1 , wherein

the first combination of mRNAs consists of FoxA2 mRNAs, or Sox17 mRNAs, or FoxA2 mRNAs and Sox17 mRNAs, or FoxA2 mRNAs, Sox17 mRNAs, GATA4 mRNAs, and GATA6 mRNAs;

the second combination of mRNAs consists of Hex mRNAs, or Tbx3 mRNAs, or Hex mRNAs and Tbx3 mRNAs, or Tbx3, GATA4, GATA6, and Hex mRNAs; and

the third combination of mRNAs consists of HNF1a mRNAs, or HNF4a mRNAs, HNF4a mRNAs, HNF1a mRNAs, HNF6 mRNAs, CEB/Pa, and CEB/Pb mRNAs.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2017
From: WANG, JIWU; NI, YUHUI; ZHAO, YUANYUAN
To: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.
Reel/Frame 044156/0923 →
Continuity (2)
Provisional Application 62423113 · Nov 16, 2016
Related Publication 20180135023A1 · May 17, 2018
References Cited (97)
US 20120021511A1 · D'Amour et al. · 2012 [cited by applicant]
US 20120129262A1 · West et al. · 2012 [cited by applicant]
US 20120190059A1 · Deng et al. · 2012 [cited by applicant]
US 20120207744A1 · Mendlein et al. · 2012 [cited by applicant]
US 20120231490A1 · Mizuguchi · 2012 [cited by examiner]
US 20130029416A1 · Thatava et al. · 2013 [cited by applicant]
US 20130302295A1 · Wang et al. · 2013 [cited by applicant]
US 20140087416A1 · Simeonov et al. · 2014 [cited by applicant]
US 20140315753A1 · Guye et al. · 2014 [cited by applicant]
US 20140349401A1 · Wang et al. · 2014 [cited by applicant]
US 20150240235A1 · Collombat · 2015 [cited by applicant]
US 20150376574A1 · Talavera-Adame et al. · 2015 [cited by applicant]
US 20160032287A1 · Sengupta et al. · 2016 [cited by applicant]
US 20160177267A1 · Melton · 2016 [cited by applicant]
CN 101541953A · 2009 [cited by applicant]
CN 102017264A · 2011 [cited by applicant]
CN 102286535A · 2011 [cited by applicant]
CN 103037939A · 2013 [cited by applicant]
CN 103374546A · 2013 [cited by applicant]
CN 104166316A · 2014 [cited by applicant]
CN 104520424A · 2015 [cited by applicant]
CN 104755607A · 2015 [cited by applicant]
CN 105358680A · 2016 [cited by applicant]
EP 1885704A2 · 2008 [cited by applicant]
EP 2532741A1 · 2012 [cited by applicant]
JP WO2009157562A1 · 2011 [cited by applicant]
JP 2012533310A · 2012 [cited by applicant]
JP 2013252081A · 2013 [cited by applicant]
JP 2015527084A · 2015 [cited by applicant]
WO WO2004106374A1 · 2004 [cited by applicant]
WO WO2006122250A2 · 2006 [cited by applicant]
WO WO2009137844A2 · 2009 [cited by applicant]
WO WO2010136583A2 · 2010 [cited by applicant]
WO WO2015184318A1 · 2012 [cited by applicant]
WO WO2014044646A1 · 2014 [cited by applicant]
WO WO2015002724A2 · 2015 [cited by applicant]
WO WO2015178397A1 · 2015 [cited by applicant]
WO WO2016134313A1 · 2016 [cited by applicant]
WO WO2016187451A1 · 2016 [cited by applicant]
WO WO2018094111A1 · 2018 [cited by applicant]
Takayama et al. Molecular Therapy 20(1):127-137, first published online Nov. 8, 2011 (Year: 2011). [cited by examiner]
Kim and Eberwine. Anal Bioanal Chem 397:3173-3178, 2010 (Year: 2010). [cited by examiner]
Akiyama et al. Development 143:3674-3685, Oct. 2016 (Year: 2016). [cited by examiner]
Warren et al. Cell Stem Cell 7:618-630, 2010 (Year: 2010). [cited by examiner]
Printout from Innoprot website printed Jan. 25, 2025, p. 1 (Year: 2025). [cited by examiner]
Delaforest, Ann et al., HNF4A is essential for specification of hepatic progenitors from human pluripotent stem cells, Development and Stem Cells, 2011, vol. 138, No. 19, pp. 4143-4153. [cited by applicant]
International Search Report/Written Opinion issued Feb. 22, 2018 in counterpart PCT Application No. PCT/US17/062102. [cited by applicant]
Si-Tayeb, Karim et al., Organogenesis and development of the liver, Developmental Cell, 2010, vol. 18, pp. 175-189. [cited by applicant]
Pagliuca, Felicia W., et al. “Generation of functional human pancreatic β cells in vitro.” Cell 159.2 (2014): 428-439. [cited by applicant]
Tsankov, Alexander M., et al. “Transcription factor binding dynamics during human ES cell differentiation.” Nature 518.7539 (2015): 344-349. [cited by applicant]
Jaramillo, Maria, et al. “Potential for pancreatic maturation of differentiating human embryonic stem cells is sensitive to the specific pathway of definitive endoderm commitment.” PloS one 9.4 (2014): e94307, 14 pages. [cited by applicant]
Liu, Jennifer SE, and Matthias Hebrok. “All mixed up: defining roles for β-cell subtypes in mature islets.” Genes & Development 31.3 (2017): 228-240. [cited by applicant]
Clardy, Susan M., et al. “Rapid, high efficiency isolation of pancreatic β-cells.” Scientific Reports 5 (2015): 13681, 9 pages. [cited by applicant]
Kim, Tae Kyung, and James H. Eberwine. “Mammalian cell transfection: the present and the future.” Analytical and Bioanalytical Chemistry 397.8 (2010): 3173-3178. [cited by applicant]
International Search Report/Written Opinion issued Feb. 27, 2018 in counterpart PCT Application No. PCT/US2017/062105, 16 Pages. [cited by applicant]
Liew, C-G., Generation of Insulin-Producing Cells From Pluripotent Stem cells: From The Selection of Cell Sources to the Optimization of Protocols, The Review of Diabetic Studies, 2010, vol. 7, No. 2, pp. 82-92. [cited by applicant]
Schiesser, J.V. et al., Derivation of Insulin-producing beta Cells From human pluripotent Stem cells, The Review of Diabetic Studies, 2014, vol. 11, No. 1, pp. 6-18. [cited by applicant]
Office Action and Search Report in Russian Counterpart Application No. 2019118438, dated Mar. 22, 2021, in 10 pages; English translation provided. [cited by applicant]
Verhovskaya L.Z. et al., “The effect of glycerin alkoxysubstituent on the morphofunctional properties of a regrafted culture” Cryobiology, 1990 (p. 30-33); English abstract provided. [cited by applicant]
Office Action in Japan Counterpart Application No. 2019-525968, dated Sep. 21, 2021, in 2 pages; English translation provided. [cited by applicant]
Office Action in Japan Counterpart Application No. 2019-525963, dated Sep. 14, 2021, in 2 pages; English translation provided. [cited by applicant]
Badieyan, Zohreh Sadat, and Todd Evans. “Concise review: application of chemically modified mRNA in cell fate conversion and tissue engineering.” Stem Cells Translational Medicine 8.8 (2019): 833-843. [cited by applicant]
Corritore, Elisa, et al. “V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells.” Stem Cells Translatio… [cited by applicant]
Extended European Search Report in EP Application No. 17872724.4, dated Oct. 5, 2020, in 9 pages. [cited by applicant]
Extended European Search Report in EP Application No. 17872174.2, dated Oct. 28, 2020, in 10 pages. [cited by applicant]
Guo, Xing Rong, et al. “PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro.” Clinical and Experimental Medicine 15.4 (2015): 501-509, published online… [cited by applicant]
Koblas, T., et al. “Reprogramming of Human Pancreatic Organoid Cells into Insulin-Producing β-Like Cells by Small Molecules and in Vitro Transcribed Modified mRNA Encoding Neurogenin 3 Transcription Factor.” Folia Biolo… [cited by applicant]
Li, Mo, et al. “Cell fate conversion by mRNA.” Stem Cell Research & Therapy 2.1 (2011): 5, 3 pages. [cited by applicant]
Rosa, Alessandro, and Ali H. Brivanlou. “Synthetic mRNAs: powerful tools for reprogramming and differentiation of human cells.” Cell Stem Cell 7.5 (2010): 549-550. [cited by applicant]
Search Report in Singapore Application No. 11201904155W, dated Aug. 10, 2020, in 2 pages. [cited by applicant]
Search Report in Singapore Application No. 11201904154X, dated Aug. 10, 2020, in 2 pages. [cited by applicant]
Sauer, Vanessa, et al. “Induced pluripotent stem cells as a source of hepatocytes.” Current Pathobiology Reports 2.1 (2014): 11-20. [cited by applicant]
Warren, Luigi, et al. “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.” Cell Stem Cell 7.5 (2010): 618-630. [cited by applicant]
Van Pham, Phuc, et al. “Improved differentiation of umbilical cord blood-derived mesenchymal stem cells into insulin-producing cells by PDX-1 mRNA transfection.” Differentiation 87.5 (2014): 200-208. [cited by applicant]
Warren, Luigi, et al. “Feeder-free derivation of human induced pluripotent stem cells with messenger RNA.” Scientific Reports 2 (2012): 657, 7 pages. [cited by applicant]
Office action in Russian Counterpart Pat. Appln. No. 2019118438, dated Jun. 17, 2022, in 6 pages; English translation provided. [cited by applicant]
Wang, H., et al. “MAFA controls genes implicated in insulin biosynthesis and secretion.” [cited by applicant]
Soria, Bernat. “In-vitro differentiation of pancreatic β-cells.” [cited by applicant]
Wang, Xiao Li, et al. “Gene manipulation of human embryonic stem cells by in vitro-synthesized mRNA for gene therapy.” Current Gene Therapy 15.4 (2015): 428-435. [cited by applicant]
Wang, Xiao Li, et al. “Reprogramming human umbilical cord mesenchymal stromal cells to islet-like cells with the use of in vitro—synthesized pancreatic-duodenal homebox 1 messenger RNA.” Cytotherapy, 2014; 16: 1519-1527. [cited by applicant]
Zhang, Donghui, et al. “Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells.” Cell Research (2009) 19: 429-438. [cited by applicant]
Xiaohui Su et al., “How to make hepatocytes by lineage reprogramming” Chemistry of Life, (2016) 4: 449-456; English abstract provided. [cited by applicant]
Jun, Zhao, et al.. “Three-dimensional culture of porcine hepatocytes for bioartificial liver.” [cited by applicant]
Search Report in Office action in Chinese Counterpart Pat. Appln. No. 201780071036.0, dated Oct. 26, 2022, in 9 pages. [cited by applicant]
Search Report in Office action in Chinese Counterpart Pat. Appln. No. 201780071029.0, dated Oct. 26, 2022, in 9 pages. [cited by applicant]
Zheng, Yang, et al. “Main transcription factors and related mechanisms of embryonic stem cells differentiation into pancreatic endocrine cells.” Journal of Clinical Rehabilitative Tissue Engineering Research 14.19 (2010… [cited by applicant]
Li, C. H., et al. “Study of the growth and secretion of microencapsulated pancreatic B cell line in vitro.” Zhongguo Ying Yong Sheng li xue za zhi= Zhongguo Yingyong Shenglixue Zazhi= Chinese Journal of Applied Physiolo… [cited by applicant]
Hua, Jiang “TAT-PDX1 protein induces the differentiation of human fetal liver mesenchymal stem cells into islet beta cells” Journal of Clinical Rehabilitative Tissue Engineering Research, Jan. 1, 2009 vol. 13, No. 1, 48… [cited by applicant]
Huang, Yan, et al. “Transcriptome analysis of induced pluripotent stem cell (iPSC)-derived pancreatic β-like cell differentiation.” Cell Transplantation 26.8 (2017): 1380-1391. [cited by applicant]
Mehrabi, Arianeb, et al. “A systematic review of localization, surgical treatment options, and outcome of insulinoma.” Pancreas 43.5 (2014): 675-686. [cited by applicant]
Okabayashi, Takehiro, et al. “Diagnosis and management of insulinoma.” World Journal of Gastroenterology: WJG 19.6 (2013): 829, 9 pages. [cited by applicant]
Davis, Robert L., et al. “Expression of a Single Transfected cDNA Converts Fibroblasts to Myoblasts.” Cell, vol. 51, 987-1000, Dec. 24, 1987. [cited by applicant]
Kajiwara, Masatoshi, et al. “Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells.” Proceedings of the National Academy of Sciences 109.31 (2012): 12538-12543, with Supporting … [cited by applicant]
Tapscott, Stephen J., et al. “MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts.” Science 242.4877 (1988): 405-411. [cited by applicant]
Tomizawa, Minoru, et al. “Improved Survival and Initiation of Differentiation of Human Induced Pluripotent Stem Cells to Hepatocyte-Like Cells upon Culture in William's E Medium followed by Hepatocyte Differentiation In… [cited by applicant]
Yamamizu, Kohei, et al. “Identification of transcription factors for lineage-specific ESC differentiation.” Stem Cell Reports 1.6 (2013): 545-559, with Supplemental Information, 9 pages. [cited by applicant]
Han, Jianyong, et al. “Tbx3 improves the germ-line competency of induced pluripotent stem cells.” Nature 463.7284 (2010): 1096-1100. [cited by applicant]